Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: A systematic comparison of 3- and 6-month response rates in trials of biologic agents.
Annals of Rheumatic Diseases, 10/08/09
Boers M et al. – The placebo phase of registration trials for RA can be limited to 3 months. An accompanying viewpoint proposes to then switch placebo patients to standard of care, allowing a more valid and comprehensive assessment including safety.
Methods- Meta-analysis of placebo- or active control trials of biologic agents in DMARD-IR RA, comparing the contrast in ACR response between experimental and control groups at 3 and 6 months
- 20 trials yielded 15 placebo and 18 active control contrasts (>10,000 patients)
- At 3 months active treatment showed highly significant contrast with placebo for ACR20 and -50 in every instance
- As all groups improved further the mean contrast at 6 months was unchanged
- For ACR70 contrast was clearly greater at 6 months due to further improvement only in experimental groups
- In active control trials contrasts were smaller, for ACR50 and-70 these decreased somewhat due to 'catch-up' responses in control groups
Maarten Boers, 11/03/09
| In the print edition hopefully appearing soon, I've outlined a new trial design that encorporates the above findings: patients in the placebo group are mandatorily switched to standard of care (usually anti-TNF) after 3 months. This allows secondary head-to-head comparisons. Please note that I'm NOT advocating that the total trial duration should be limitied to 3 months. |
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
Annals of Rheumatic Diseases, 11/24/09
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis
Annals of Rheumatic Diseases, 11/23/09
Article Search
Sponsor


See Latest Articles


